DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+13.75%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$2.18B
AUM Growth
+$2.18B
(+23%)
Cap. Flow
+$262M
Cap. Flow
% of AUM
12.01%
Top 10 Holdings %
Top 10 Hldgs %
32.65%
Holding
150
New
47
Increased
20
Reduced
25
Closed
28
Top Buys
| 1 |
Labcorp
LH
|
$69.7M |
| 2 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$68.6M |
| 3 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
$61.2M |
| 4 |
ITMN
INTERMUNE INC
ITMN
|
$53M |
| 5 |
AbbVie
ABBV
|
$52.7M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$50.3M |
| 2 |
Humana
HUM
|
$42.8M |
| 3 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
$42M |
| 4 |
Globus Medical
GMED
|
$34.2M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
$30.3M |
Sector Composition
| 1 | Healthcare | 49.23% |
| 2 | Technology | 1.36% |
| 3 | Financials | 0.63% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
1
Avadel Pharmaceuticals
AVDL
$1.43B
| $70.5M | 2.88% | 5,258,475 +925,000 | +21% | +$12.4M |
|
|
AUXL
2
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $69.8M | 2.85% | 2,566,705 -1,546,680 | -38% | -$42M |
|
|
3
Labcorp
LH
$23.1B
| $69.7M | 2.85% | +709,689 | New | +$69.7M |
|
|
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $68.6M | 2.8% | +2,428,569 | New | +$68.6M |
|
|
QCOR
5
DELISTED
QUESTCOR PHARMA INC
QCOR
| $67.5M | 2.76% | 1,039,865 -466,432 | -31% | -$30.3M |
|
|
ASPX
6
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
| $61.2M | 2.5% | +1,988,990 | New | +$61.2M |
|
|
ARRY
7
DELISTED
Array Biopharma Inc
ARRY
| $57.4M | 2.34% | 12,205,673 +970,267 | +9% | +$4.56M |
|
|
ITMN
8
DELISTED
INTERMUNE INC
ITMN
| $53M | 2.16% | +1,583,942 | New | +$53M |
|
|
INFI
9
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $52.8M | 2.16% | 4,444,027 +462,284 | +12% | +$5.5M |
|
|
10
AbbVie
ABBV
$372B
| $52.7M | 2.15% | +1,025,000 | New | +$52.7M |
|
|
NXTM
11
DELISTED
NxStage Medical Inc.
NXTM
| $48.4M | 1.98% | 3,801,175 -1,769,464 | -32% | -$22.5M |
|
12
Insmed
INSM
$28.8B
| $38.4M | 1.57% | 2,016,147 +963,902 | +92% | +$18.4M |
|
|
DYAX
13
DELISTED
DYAX CORPORATION
DYAX
| $34M | 1.39% | 3,786,478 +428,731 | +13% | +$3.85M |
|
|
BDSI
14
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $33.6M | 1.37% | 3,986,760 +2,226,035 | +126% | +$18.8M |
|
|
ATRS
15
DELISTED
Antares Pharma, Inc.
ATRS
| $33.2M | 1.36% | 9,488,461 -652,713 | -6% | -$2.28M |
|
|
TRNX
16
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $33M | 1.35% | 1,554,075 +44,101 | +3% | +$936K |
|
|
UAM
17
DELISTED
Universal American Corp
UAM
| $32.5M | 1.33% | 4,600,993 +301 | +0% | +$2.13K |
|
|
AIRM
18
DELISTED
Air Methods Corp
AIRM
| $29.5M | 1.21% | 552,544 +307,252 | +125% | +$16.4M |
|
19
Pacific Biosciences
PACB
$393M
| $28.9M | 1.18% | 5,406,110 +1,054,848 | +24% | +$5.64M |
|
20
McKesson
MCK
$85.4B
| $28.8M | 1.18% | +163,000 | New | +$28.8M |
|
21
Medtronic
MDT
$119B
| $28.6M | 1.17% | +464,000 | New | +$28.6M |
|
22
Merck
MRK
$210B
| $27.1M | 1.11% | 477,200 -247,800 | -34% | -$14.1M |
|
|
AGN
23
DELISTED
ALLERGAN INC
AGN
| $26.8M | 1.09% | 215,636 +63,636 | +42% | +$7.9M |
|
|
GEVA
24
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $26.4M | 1.08% | +317,678 | New | +$26.4M |
|
25
Quest Diagnostics
DGX
$20.3B
| $25.5M | 1.04% | +440,303 | New | +$25.5M |
|